GBP116.00
1.58% day before yesterday
London, Feb 07, 05:41 pm CET
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

AstraZeneca Target price 2025 - Analyst rating & recommendation

AstraZeneca Classifications & Recommendation:

Buy
82%
Hold
18%

AstraZeneca Price Target

Target Price GBP136.04
Price GBP116.00
Potential 17.27%
Number of Estimates 25
25 Analysts have issued a price target AstraZeneca 2026 . The average AstraZeneca target price is GBP136.04. This is 17.27% higher than the current stock price. The highest price target is GBP179.71 54.92% , the lowest is GBP104.83 9.63% .
A rating was issued by 33 analysts: 27 Analysts recommend AstraZeneca to buy, 6 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2026 of 17.27% . Most analysts recommend the AstraZeneca stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029


Dec '24 2025
Estimates
Revenue Billion GBP 42.32 45.81
14.82% 8.25%
EBITDA Margin 32.54% 35.36%
3.91% 8.67%

25 Analysts have issued a sales forecast AstraZeneca 2025 . The average AstraZeneca sales estimate is GBP45.8b . This is 8.27% higher than the revenue of the last 12 months(TTM). The highest sales forecast is GBP47.9b 13.26% , the lowest is GBP43.1b 1.76% .

This results in the following potential growth metrics:

Revenue Estimates

2024 GBP42.3b 14.82%
2025 GBP45.8b 8.25%
2026 GBP48.8b 6.50%
2027 GBP51.4b 5.45%
2028 GBP54.3b 5.58%
2029 GBP57.3b 5.47%

18 Analysts have issued an AstraZeneca EBITDA forecast 2025. The average AstraZeneca EBITDA estimate is GBP16.2b . This is 17.66% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is GBP19.2b 39.22% , the lowest is GBP14.0b 1.50% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 GBP13.8b 19.32%
2025 GBP16.2b 17.63%
2026 GBP17.8b 10.07%
2027 GBP19.8b 10.79%
2028 GBP20.2b 2.06%
2029 GBP23.8b 18.15%

EBITDA Margin

2024 32.54% 3.91%
2025 35.36% 8.67%
2026 36.54% 3.34%
2027 38.39% 5.06%
2028 37.11% 3.33%
2029 41.57% 12.02%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029


Dec '24 2025
Estimates
Earnings Per Share GBP 3.55 5.27
14.89% 48.45%
P/E 22.03
EV/Sales 4.36

17 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is GBP5.27 . This is 48.03% higher than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is GBP6.09 71.07% , the lowest is GBP3.31 7.02% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 GBP3.55 14.89%
2025 GBP5.27 48.45%
2026 GBP6.24 18.41%
2027 GBP6.99 12.02%
2028 GBP8.03 14.88%
2029 GBP9.29 15.69%

P/E ratio

Current 32.59 2.75%
2025 22.03 32.40%
2026 18.58 15.66%
2027 16.59 10.71%
2028 14.44 12.96%
2029 12.49 13.50%

Based on analysts' sales estimates for 2025, the AstraZeneca stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 4.36 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 3.93 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.72 3.67%
2025 4.36 7.68%
2026 4.09 6.11%
2027 3.88 5.17%
2028 3.67 5.29%
2029 3.48 5.18%

P/S ratio

Current 4.25 2.83%
2025 3.93 7.64%
2026 3.69 6.11%
2027 3.50 5.17%
2028 3.31 5.29%
2029 3.14 5.18%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today